In short
Podcast Summary: Bloomberg Businessweek Episode - Nvidia Expects to Make $1 Trillion From AI Chips Through 2027
Episode Overview In this episode, hosts Carol Massar and Tim Stenovec discuss Nvidia's ambitious forecast regarding its AI chip revenue, as presented by CEO Jensen Huang during the company's GTC event. Nvidia anticipates generating $1 trillion from its Blackwell and Rubin AI chips by the end of 2027, significantly raising their previous estimate. The discussion also touches on Nvidia's market position, competition, technological advancements, and the broader implications of AI chip demand.
Key Points
Nvidia's Revenue Forecast
- New Projection: Nvidia expects to make $1 trillion from AI chips through 2027, a substantial increase from their earlier forecast of $500 billion by the end of 2026.
- Market Reaction: Initially, Nvidia shares soared by 4.8% but later adjusted to 2% gains, indicating cautious investor sentiment regarding the sustainability of growth.
- Revenue Sources: Approximately 60% of the projected revenue is expected to come from hyperscalers, highlighting Nvidia's reliance on major cloud computing providers.
Market Dynamics and Competition
- Investor Concerns: Investors are looking for confirmation of continued market growth amid increasing competition from peers like Advanced Micro Devices (AMD) and clients developing in-house chip solutions.
- Technological Development: Nvidia aims to refresh its entire product lineup annually, emphasizing the importance of staying ahead in innovation.
Upcoming Product Launches
- New AI Processors: The next generation of Nvidia's flagship AI processors, named Vera Rubin, is set to debut in the second half of 2026.
- Performance Metrics: The Vera Rubin processors are expected to deliver twice the performance of existing CPUs, expanding Nvidia's offerings beyond GPUs.
Expert Guest Insights
- Ed Ludlow, co-host of Bloomberg Tech:
- Clarifies the significance of the new revenue projection, emphasizing that it represents an extension rather than an acceleration of Nvidia’s growth trajectory.
- Discusses the competitive landscape, noting that while Nvidia's advancements are noteworthy, the broader market dynamics will significantly impact future performance.
Broader Economic Implications
- AI and Workforce Integration: Companies like IBM are integrating AI technology into operational systems, showcasing AI's tangible benefits in business functions.
- Market Trends: The episode highlights how Nvidia's growth in the AI sector reflects a larger trend in technology and finance, where AI capabilities are reshaping market strategies.
Conclusion The episode provides an in-depth look at Nvidia's forecasts and the implications for the tech landscape, focusing on the company's dominance in AI chip manufacturing, the challenges posed by competition, and the broader economic context surrounding AI integration in business operations. The insights from the guests offer a balanced perspective on Nvidia's future, investor expectations, and the evolving technological landscape.
For more updates, the episode encourages listeners to tune into Bloomberg Businessweek live on YouTube and follow ongoing discussions around technology and finance trends.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Chapters
Tap a time to open that second in VONVIDIA's Financial Outlook
0:30 to 2:14
Discussion on NVIDIA's expectation to generate $1 trillion in AI chip revenue.
“So there's a lot of noise about AI, but time's too tight for more promises.”
Market Reaction to NVIDIA Forecast
2:14 to 4:48
Analysis of the market's reaction to NVIDIA's new financial projections.
“because shares of NVIDIA were up as much as 4.8%.”
NVIDIA's CPU Market Strategy
4:48 to 7:16
Exploration of NVIDIA's strategy to enter the CPU market and its implications.
“And it seems as if actually it swung back to being heavily a majority being around the hyperscalers.”
AI Hardware Developments
7:16 to 10:30
Insights into NVIDIA's new hardware developments and their significance.
“So NVIDIA has been hinting for a few months that they're going to go harder after the CPU market.”
U.S. Allies and the Strait of Hormuz
14:46 to 21:39
Discussion on U.S. allies' response to the Strait of Hormuz situation and Trump's demands.
“allies deflecting President Trump's demands to help reopen the Strait of Hormuz, expressing unease about getting pulled into that war, U.S.”
Acadia Pharmaceuticals Update
21:41 to 22:29
Acadia Pharmaceuticals' CEO discusses the regulatory challenges for their drug and the European situation.
“We know it's later over there in London.”
Interview with Acadia Pharmaceuticals CEO
25:01 to 28:06
Catherine Owen Adams discusses Acadia's drug approval process and challenges in the EU.
“You're listening to the Bloomberg Business Week Daily Podcast.”
FDA Approval Process Insights
28:06 to 29:40
Gain insights into the FDA approval process and how it maintains safety standards.
“Give us some insights, since you guys have to deal with it on a day-to-day basis.”
Affordability Challenges in Pharmaceuticals
29:40 to 31:27
Learn about the impact of affordability pressures on pharmaceutical companies.
“How is that kind of affecting you as a pharmaceutical company?”
Understanding Pharmacy Benefit Managers
31:27 to 32:54
Explore the role of pharmacy benefit managers and their impact on drug pricing.
“And just as you think about different health systems, and everything has pluses and minuses.”
Show all 12 chapters
Industry Perspectives on Current Challenges
32:54 to 33:30
Hear perspectives on the macro environment and the pharmaceutical industry.
“In terms of the macro, how do you feel about the environment with everything that's going on?”
Macro Economic Insights with JP Morgan
38:00 to 42:05
Deep dive into macroeconomic factors affecting investment strategies.
“No, Aaron, I want to ask you, you guys, JPMorgan Asset Management, $4.1 trillion in assets under supervision.”
Transcript
Automatic transcript. May contain errors.0:00Carol Massar:They told us to expect change. They warned us about the transition. But honestly, they forgot the best part. This is the chapter where we finally focus on us. LifeMD delivers expert menopause and midlife care right from your home. From hormone health to holistic wellness, LifeMD helps you feel your best for the best years of your life. LifeMD, it's just getting good. Visit LifeMD.com slash goodlife. So there's a lot of noise about AI, but time's too tight for more promises. So let's talk about results. At IBM, we work with our employees to integrate technology right into the systems they need.
0:40Now, a global workforce of 300 ,000 can use AI to fill their HR questions, resolving 94 % of common questions. Not noise. Proof of how we can help companies get smarter by putting AI where it actually pays off, deep in the work that moves the business. Let's create smarter business.
1:27IBM. The Wise Multicurrency Account is for you. Be smart. Get wise. Download the Wise app today or visit wise.com. Terms and conditions apply.
1:40Carol Massar:Bloomberg Audio Studios. Podcasts. Radio. News. This is Bloomberg Business Week Daily. Reporting from the magazine that helps global leaders stay ahead. With insight on the people, companies, and trends shaping today's complex economy. plus global business, finance, and tech news as it happens. The Bloomberg Businessweek Daily Podcast with Carol Masser and Tim Stenebeck on Bloomberg Radio. I want to go now back to San Francisco and talk a little bit about NVIDIA because shares of NVIDIA were up as much as 4.8%. Now they're up just about 2%. NVIDIA expects to make a trillion dollars from AI chips through 2027.
2:24That's just one of the headlines. the latest forecast delivered by CEO Jensen Wan during the company's GTC event, extending the outlook. I want to bring in Ed Ludlow. He's the co-host of Bloomberg Tech on Bloomberg TV. Ed, these were some of the numbers that we were waiting for. Just give us some context around these figures and what we knew and what is new here. So$1 trillion, which is a range between 2025 and the end of 2027. The prior figure was$500 billion, which was stated on October 28th of last year over a period of five fiscal quarters through the end of calendar 2026. So what this new number is,$1 trillion between 2025 and the end of 2027, it doesn't represent an acceleration nor an expansion of the outlook that NVIDIA had kind of given.
3:20It's not saying that growth is accelerating beyond the prior trend. What they are doing is making that outlook further out. They're telling us what they see through the end of next year, 2027. And the market reaction represents, you know, the line chart, bring up your GIP on the terminal of Nvidia shares. Massive spike when Jensen Wang said it on stage. And then Wall Street did the math. They realized this was just the natural progression of how things would go if things stayed at what he announced in October. Yeah. I mean, it's very, very complicated because you can't say this is what they're tracking out on a on a quarter basis going forward.
4:02The original forecast was just Blackwell Rubin systems. It was stated out loud by Jensen Wang on October 28th. And then it was a mismatch between a forecast for five fiscal quarters against a dateline of the end of this calendar year, 2026. There's another data point within it. And I posted the slide on X. There's a pie chart that they shared with it. What's really interesting is that NVIDIA is saying that 60%, 6-0 % of that revenue opportunity is coming from the hyperscalers still. Just those four big cloud computing providers. And the reason that's important is that that with NVIDIA has been something very closely tracked, how much they're reliant on the hyperscalers only and how diversified their customer base is.
4:48And it seems as if actually it swung back to being heavily a majority being around the hyperscalers.
4:54Carol Massar:You know, I did the same thing because I saw the number and I'm like trying to understand. I'm like, where's that? I need some context. And I was looking at, was it the CES reporting that Ian and you guys all did reporting? And he at that point was talking about five hundred billion dollars, right, in revenue by the end of 2026. And I think an opportunity that it could eclipse that. So so we need to kind of I don't know, is there a question you would ask Jensen at this point off of this number or off of this? Yeah. Why didn't you guys file an 8K or put it in writing so the market could understand it?
5:32And actually, like, I don't know, I think that the market might sympathize with me on that question. Ed, is the reason it's because he wants something flashy for this event that he holds twice a year? Look, I am in the sequence, like, you know, the video will be available for people to watch back. Right. But in the sequence of presenting that number, what Jensen Wang was saying was, you know, I presented to you this five hundred billion dollar figure. And then he kind of make a joke that no one gave them credit for it or no one was wowed by it. And he paused and he said, as I stand right here today, we now see one trillion dollars through the end of 2027.
6:13And, you know, for them, it was a really big moment. I'm really finding it difficult to pass. We're discussing it as a team in the IB about how do you word that and mismatch the, I'm trying to reconcile fiscal quarters with calendar quarters. What I would say is when that$500 billion came out after GTCDC, what happened was the sell side went away and baked it into what they modeled. And then that started showing up in the estimates. And so at least we can say, oh, aren't we lucky that in the coming days, maybe people, you go on MODL on the Bloomberg and those numbers will be updated a little bit.
6:52Okay, so in the meantime, we are getting some other headlines. I don't know if you have a chance to see these. The company is saying that Vera has twice the performance of any CPU. Jensen says the CPU, quote, for sure, is a multi-billion dollar business or multi-billion business, rather. What about the latest from Vera at NVIDIA? and how this changes the equation in hardware. Is this new to you? So NVIDIA has been hinting for a few months that they're going to go harder after the CPU market. And that was confirmed first with CoreWeaver as having access to it and then Meta as the CPU being sold as a standalone product.
7:35If you look at the market right now, in the moment that the headlines hit, there's no sharp reaction in AMD or Intel to the downside. because the market's kind of baked that in that NVIDIA would do this. CPUs are not as valuable to NVIDIA as GPUs are. The cost per CPU and where the CPU fits in the server design, you know, it's a general purpose processor. It doesn't have the sort of AI workload specific use case that a GPU has. But it's an addressable market that NVIDIA can go over to boost the overall TAM. and do something different that they've not already done. And there are loads of use cases where you might have data center infrastructure built that NVIDIA's GPUs are not a part of the plans, but that CPU would come in quite useful.
8:28Carol Massar:Hey, one other headline I want to ask you about. Jetson Wong talking and showing off the new Rubin Ultra system. And this plays into agentic AI, which I feel like when I have AI conversations now, increasingly people are moving in that direction. What do we need to know about that? Is that a big mover? Yeah. Or no? No. Knowing so far is that like, you know, NVIDIA is committed to bringing out a new generation of platform on an annual basis. The details of the Rubin-based platforms have been released. And, you know, in terms of literally the energy it takes to power that thing relative to the Blackwell system, it's a big step up.
9:11tokens generated it's a big step up it's a much more efficient system but those data points aren't that new you know they've been specked out already and discussed huh which don't go to don't go too
9:24Carol Massar:far ahead it kind of explains though the trade right like we got this kick up of more than four percent and now we're just up about 1.67 which i think was lower than where it was before it is the announcement because we were up two percent higher earlier in the session today we were up about 2%. Anything else you're looking at for at this point or just, we're going to, I don't know. Yeah. I mean, I ran away from my desk in the live feed to come join you guys, which is, which is good. I'm not complaining about that, but the thing that I'm not seeing is a specific announcement on an inference specific platform.
9:56You know, again, Nvidia hired Grok, Grok with the Q's CEO and other leading talent and acquired the rights to their platform. And, you know, So I think that they've hinted that at GTC, well, Jensen Wang said explicitly, at GTC, we will hear more about what they actually plan to do with that transaction. And Grok was an inference-only platform. So you'd expect NVIDIA to say, here's our offering for inference-only. Ed, for everybody, you've got to explain Grok with a Q versus Grok with a K, because I think people hear Grok. Oh, sure.
10:30Carol Massar:Yeah. Yeah, there is an AI hardware company called Grok with a Q. It makes accelerators or server systems, server designs for running AI workloads, not training them, but running them. Grok with a K is the tool, the chatbot of XAI, or indeed its model. The models are also named Grok. And XAI is Elon Musk's AI frontier lab or company, which is now owned by SpaceX, his rocket company. they are the same word spelt differently and you know what we end with the always sunny it's always sunny in Philadelphia whiteboard with Charlie I think it's Charlie just standing there you know trying to connect everything I think we should just load that into Viz or into our system for the next time I'm on sure our producer CC threw it in our chat as soon as you said it and just a reminder of kind of where we are thank you so much Ed Ludlow hopping on twice for us he is one of the co-hosts of Bloomberg Tech on Bloomberg TV Catch, Ed and Caroline Hyde, 11 a.m.
11:37Carol Massar:to 12 noon Wall Street time, Monday through Friday on Bloomberg TV. Stay with us. More from Bloomberg Business Week Daily coming up after this.
11:49Carol Massar:They told us to expect change. They warned us about the transition. But honestly, they forgot the best part. This is the chapter where we finally focus on us. LifeMD delivers expert menopause and midlife care right from your home. From hormone health to holistic wellness, LifeMD helps you feel your best for the best years of your life. LifeMD, it's just getting good. Visit LifeMD.com slash goodlife. Support for the show comes from Public. Public is an investing platform that offers access to stocks, options, bonds, and crypto. And they've also integrated AI with tools that can assist investors in building customized portfolios.
12:31One of these tools is called Generated Assets. It allows you to turn your ideas into investable indexes. So let's say you're interested in something specific like biotech companies with high R &D spend, small cap stocks with improving operating margins, or the S &P 500 minus high debt companies. Chances are there isn't an ETF that fits your exact criteria. But on public, you just type in a prompt and their AI screens thousands of stocks and build a one-of-a-kind index. You can even backtest it against the S &P 500. Then you can invest in a few clicks. Go to public.com slash market and earn an uncapped 1 % bonus when you transfer your portfolio.
13:10That's public.com slash market.
13:25All investing involves risk of loss. See complete disclosures at public.com slash disclosures.
13:31Carol Massar:Small businesses are the pulse of every community. They bring people together, create opportunities, and drive growth. With a widespread presence in communities across the country, Chase for Business supports small business owners at a local level. That makes it possible for you to connect, learn from each other, and grow together. There's a real commitment to seeing small businesses succeed. The Chase for Business team has knowledge and expertise that span a wide range of financial areas. They can help you make more informed decisions as you navigate the complexities of running your business.
14:03Carol Massar:They'll help your business grow with individual guidance and convenient digital tools all in one place. With that guidance and your determination, you can take your business farther and help build a brighter future for your community. Learn more at chase.com slash business. Chase for business, make more of what's yours. The Chase mobile app is available for select mobile devices, Message and data rates may apply. JPMorgan Chase Bank N.A., member FDIC. Copyright 2026, JPMorgan Chase and Company. You're listening to the Bloomberg Business Week Daily Podcast. Catch us live weekday afternoons from 2 to 5 Eastern.
14:39Carol Massar:Listen on Apple CarPlay and Android Auto with the Bloomberg Business app or watch us live on YouTube. While U.S. allies deflecting President Trump's demands to help reopen the Strait of Hormuz, expressing unease about getting pulled into that war, U.S. war in Iran, President Trump spoke about it less than two hours ago from the White House. Their capacity to threaten commercial shipping in the Strait of Hormuz with more than 30 mine laying ships destroyed. So we want them to come and help us with the Strait. We have it in very good shape. Numerous countries have told me they're on the way. Some are very enthusiastic about it, and some are.
15:23And some are countries that we've helped for many, many years. We've protected them from horrible outside sources, and they weren't that enthusiastic.
15:36Carol Massar:That, of course, is President Trump at the White House earlier today. Well, the U.S. request for a NATO assist comes at a time when Bloomberg Opinions Mark Champion, who covers Europe, Russia, and the Middle East for us, writes about how essentially U.S. allies can put a high price on helping out the United States in the Strait of Hormuz. It's all about maybe being in the driver's seat a little bit. Maybe. This is what we want to hear from Mark about. Hey, Mark joins us right now. Mark Champion, that is, from London. Mark, it is good to have you here with Tim and myself. You know, after a year where President Trump seems to have had the edge on U.S.
16:11Carol Massar:allies on a lot of different fronts and situations. Have the tables turned a bit here and are U.S. allies a little bit more perhaps in the driver's seat? Well, it's not, you know, they're still dependent on the U.S. for security. There's limits to what they can do. But the point is that here is an instance where, you know, when he says, you know, this is a NATO, you know, NATO needs to respond. You know, NATO doesn't need to respond. This, you know, NATO has a defense clause, collected defense clause, and it's been invoked once on behalf of the U.S. You know, when when it was attacked on September 11.
16:53And, you know, this is not a war of self-defense. This is a war of choice that the U.S. made. It wasn't attacked. It decided to attack Iran. So, you know, there's no automaticity here. And basically, this is a case where, you know, Donald Trump needs some help. You know, it isn't often that the U.S. needs military help. But this is one instance where the U.S. is pretty stretched. It's got two, you know, carrier strike fleets in the Gulf. They are very busy attacking Iran. and it isn't actually militarily very easy to sort of split that out and begin a you know an operation to protect shipping on its way through the gulf also you know some of the countries that he's asked the uk france japan south korea these are countries that are actually pretty good at demining.
17:55So if the Iranians have demined, they have the kit, they have, you know, drone demining equipment, which is what you want in a, you know, conflicted zone like this. But, you know, the point is that, you know, because he needs them, you know, it isn't just about raising the oil, I mean, controlling the oil price. So that, you know, that's why you want the straits open. But he needs it because that is where the war is being fought. He needs it in order to win the war. And so they should do what Donald Trump would do, which is to say, OK, if you're going to ask us to put our ships and sailors at risk, then we have certain conditions and we have a price.
18:39What would the price be? What would the conditions be in your view, Mark? How would Donald Trump handle this if he were on the other side? Yeah, I mean, so there are things that different countries will want. I would say that there are two overall things that they should be asking for. The first is for, you know, to make it for the Americans to understand and to make it clear that this is a non-American operation. In other words, to be able to separate this and be able to say we are not joining the war effort. We are operating a non-U.S. effort in order to keep the international waterways free and to keep shipping safe.
19:24You know, the Iranians will see this as an intervention because they aren't trying to keep the straits closed. But nevertheless, you know, this is a war that may not suddenly end from from one day to the next. It may drag on in different forms for some time. And it will be important for allies who didn't want to be the part of the war and don't want the consequences to to be able to sort of make that difference. and to include other countries, you know, that, you know, aren't necessarily the usual suspects of Western allies and so on in order to take part. So that's that's one thing they can do.
20:05The other thing that they can and should do is to tell him, look, you know, we know that you're not that keen on helping out Ukraine. We need Ukraine helped. You haven't been, you know, the difference between the Trump administration and the Biden administration in terms of helping out on Ukraine is pretty stark. So, you know, we have a minimal demand to make. And that really should be that the U.S. continues to provide Patriot missiles, which will be at a premium after this Gulf War because of the rates at which the Gulf states have been burning through them and the U.S. bases have been burning through them.
20:43Carol Massar:Hey, before we go, Mark, just one last thing that this really jumped out in your column that's on the Bloomberg today. You remind us that the worst hit countries have been America's allies in the Persian Gulf specifically. And you say the Trump administration's failure to prioritize Gulf allies will have a long tail prompting a reassessment of their security policies. But for now, they need the Hormuz open to just real quickly, 30, 40 seconds. What might be the implications there? Yeah, I mean, I don't have a crystal ball to say how it will fall, but there's no question that the Saudis, the UAE, the Gulf states collectively, that they are going to be looking at their situation and saying, we host these U.S.
21:27bases in order to make us more secure. They made us less secure. So, you know, what are we going to do about that? And I don't know that they would know the answers at this point. I certainly don't. But they will be looking at it.
21:41Carol Massar:All right. Going to leave it there. So appreciate it. We know it's later over there in London. Mark, thank you, as always. Mark Champion's columns, I got to say, must read on the Bloomberg. So I highly recommend you check them out on the Bloomberg and at Bloomberg.com. Mark, by the way, International Affairs columnist for Bloomberg Opinion, again, joining us from London. Stay with us. More from Bloomberg Businessweek Daily coming up after this.
22:28crypto without all the bugs or the confetti. Retirement accounts, yep. High yield cash, yes again. They even have direct indexing. Public has modern design, powerful tools, and customer support that actually helps. Go to public.com slash market and earn an uncapped 1 % bonus when you transfer your portfolio. That's public.com slash market. Add paid for by Public Holdings. Brokered services by Public Investing, member FINRA SIPC. advisory services by public advisors, SEC registered advisor, crypto services by zero hash. All investing involves risk of loss. See complete disclosures at public.com slash disclosures.
23:05Carol Massar:Being a small business owner isn't just a career, it's a calling. Chase for Business knows how much heart and effort go into building something of your own. That's why they make business growth their priority. The Chase team takes the time to understand your mission, where you are now, and where you want to go. Their broad range of solutions is designed with you in mind so you can bring your ideas to life. From banking to payment acceptance to credit cards, you can conveniently manage all your business finances all in one place with their digital tools. Looking for tips and advice? Their online resources are always available to give you the solutions you need to help your business thrive.
23:43Carol Massar:See how your business can get stronger and go farther with Chase for Business. Learn more at chase.com slash business. Chase for business. Make more of what's yours. The Chase mobile app is available for select mobile devices. Message and data rates may apply. JPMorgan Chase Bank N.A. Member FDIC. Copyright 2026. JPMorgan Chase and Company. Deadlines move. Plans change. And sometimes opportunities pop up out of nowhere. When you need branded gear fast, 4imprint is ready to deliver. 4imprint offers hundreds of promotional products in their 24-hour category. Everything from custom apparel, bags, and drinkware to writing tools, trade show staples, and high-tech gear.
Read the full transcript
24:24At 4imprint, they're focused on getting the details right, printing your logo with precision, packing your order with care, and shipping it out fast. And it's backed by their 360-degree guarantee. That's 4imprint's promise your order will show up right on time, just the way you planned it. That's what it means to be 4imprint certain. So, if you're prepping for a last-minute event or jumping on a big opportunity, you don't have to settle or scramble. With 4imprint, fast, reliable service and peace of mind are built right in. Check out their full 24-hour selection at 4imprint.com. 4imprint. For certain.
25:01Carol Massar:You're listening to the Bloomberg Business Week Daily Podcast. Catch us live weekday afternoons from 2 to 5 Eastern. Listen on Apple CarPlay and Android Auto with the Bloomberg Business App. or watch us live on YouTube. Earlier this month, Acadia Pharmaceuticals said the Committee for Medicinal Products for Human Use, this is the CHMP of the European Medicines Agency, reviewed the drug. Okay. Triphenatide? Triphenatide. This is why Carol Maser is the best. You are usually like king on this stuff. For treatment of Rett syndrome in patients two years of age and older for approval in the EU, and decided the evidence didn't support approving it.
25:39Acadia said it planned to formally challenge the decision. And we're joined now once again by Catherine Owen Adams, CEO of Acadia Pharmaceuticals. It's the$3.6 billion market cap, a biopharmaceutical company. It focuses on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous systems disorder. She joins us here in the Bloomberg Interactive Brokers Studio. Welcome. It's good to see you again. Last time we spoke, you were in San Francisco at the J.P. Morgan Health Care Conference. I was, yeah. Good to be here. Thanks for having me. It's good to have you in New York.
26:07So I want to start with the trofinetide statement from European regulators for the treatment of Rett syndrome. Is there anything new? You came out a few weeks ago and said you would challenge this. What's the latest on that? Yeah, so there's nothing new since we said that. We are putting in writing our official application for reexamination, and that's going in in the next few days. And we expect that process. It's governed by a time clock, so it's pretty fixed. And that process will run probably till June. And during that time, we have the opportunity to re-state our evidence, have another scientific advisory group, and also probably have an oral explanation.
26:43So there's a lot more chance to interact with the European Union. So this drug is approved for use in the U.S. under debut? It's approved for use in the U.S.'s debut, also approved in Canada and Israel. So what's different about the European situation? Aren't they tougher? They are definitely tougher in rare disease. We have a pivotal trial, which was statistically significant across two co-primary endpoints. And the European Union has stated that they don't value the meaningful difference that that gives our RET patients. And they're finding it hard to understand the clinical value of the differentiation that we saw between the endpoints.
27:20And so we're having to educate on RET. It's not a very well understood. It's rare neurological disorder. It affects mainly young girls. There's about 12 ,000 patients in the EU, 6 ,000 in the US. So it's not very well understood, even by neurologists. So there's a lot of education that we have to continue to do. And also our patient advocacy voices are quite disparate across the EU. And now with the International Rett Syndrome Foundation helping us as well in terms of understanding what it's like to live with a child with Rett Syndrome, all of this is important now to help our re-examination process.
27:53Carol Massar:You know, speaking of a process or processes, I am wondering, Catherine, too, I think we are, we think a lot about this administration and what it's like going through a regulatory process. How has it changed? Has it calmed down? Give us some insights, since you guys have to deal with it on a day-to-day basis. Yeah, we don't have an active approval process going on right now. We actually just got our debut sticks formulation approved by the FDA in December. And actually, our process went really quite smoothly. So as I try to explain to people, we don't deal necessarily with the people at the top of the FDA.
28:31We deal with our divisions. And the division leaders and the division staff work really hard all the time to ensure that they are applying the timelines that we agreed to during the PDUFA process. And we have found so far at Acadia that all of those timelines have been stuck to. Do those individuals stay from administration to administration? They have tended to. And the people that we deal with are certainly the same people that we've been dealing with for a number of years. So that's really a positive right now.
28:56Carol Massar:Are there fewer trials? Are there faster approvals? And I think this gets to, I think, as citizens here of the United States trying to understand public safety concerns and just wondering, a process that I think many would say was a gold standard globally. Has that changed? No, I don't think so. I think the FDA still applies very high standards of safety and efficacy for our population. And I think the U.S. will continue to be the gold standard as we see the leadership changing. I think some positives have come out of it. This sort of focus on trying to be less bureaucratic, trying to think about different ways of approaching clinical trials.
29:31And so we're very positive about supporting that. But obviously, that needs to be actually put into the guidelines and the rules. So we'll see how that flows down.
29:39Carol Massar:What about when it comes to affordability and the focus on affordability? How is that kind of affecting you as a pharmaceutical company? We're also like focusing on certainly the United States on the pharmacy benefit managers, that level. Trump Rx. There is that. So just how is any of that affecting some of the business decisions? Because as you say, you guys are developing sometimes a treatment, a drug that is not inexpensive, and it's a smaller pool of patients who will use it. But there's also a little bit of misunderstanding about that. So, Debut, for example, 90 % of our patients pay less than$10 per month for their prescription.
30:18So, there's a lot of misunderstanding around that whole sort of high-priced situation. But I think, Carol, your point around pressures on affordability for the American patient, that is absolutely top of all of our minds, even as individuals, right? We all go to the pharmacy as well and see that. And so America is unique in terms of a market in that 50 cents on every dollar spent on medicine goes to middlemen. And we're the only country in the world where - So by unique. Yes, unique and special. Well, somewhat arguing efficient or maybe they're - Yes. And it's the PBMs. It's also hospitals mark up their drug prices as well.
30:54It's a lot of intermediaries that actually don't add to the patient experience at the end at the pharmacy. And we're really trying to work with our various policy groups in a bipartisan way. I think everybody agrees that it's not great for patients in terms of how we're currently structured. And we're very, very focused on supporting the administration in a bipartisan way to help us sort of get through that. My daughter got some crayons and play-doh at the hospital when she was there a few weeks ago, and I haven't gotten the bill yet.
31:23Carol Massar:I don't know what it'll be. Everything will be itemized. I think it'll be okay. How did we kind of get there? And I know you're from London. Yes. And just as you think about different health systems, and everything has pluses and minuses. I get that. It's not apple to apples in terms of comparison. But how did we get this wrong, maybe, in terms of PBMs? Because everybody thought this was going to be great for patients, for everybody. It was going to be more efficient, and the cost savings would be passed on to consumers. The idea of a middleman in terms of brokering sort of, you know, larger discounts across sort of payers, I guess it is fundamental, is a good idea.
31:58The issue is that the rebates that the pharmaceutical manufacturers give to the PBM should be passed along to patients, and yet they're not. And so that's the point where we're really trying to sort of unpick the systems that have got us to where we are now. And ensure that those rebates that we do give actually do get to the patients that they were intended for. and that is actually written into the contracts and into the into the sort of the legislation
32:21Carol Massar:and that actually happens i have to say i always find that whole process like why is there a rebate like who gets a rebate and how does it work it just seems to me so well the idea is you get the coupon and then you don't use it so why don't we just mark down the drug to begin with because then that will be a guarantee of a decline in revenue rather than you actually taking the time to get the coupon and going in and well the middlemen are so entrenched now in our health care system It's really quite hard right now to sort of try and take them out and just get these discounts to the patient at the pharmacy counter.
32:54Okay. I'm glad we settled everything. We solved it all.
32:58Carol Massar:30 seconds. I know we have to run. In terms of the macro, how do you feel about the environment with everything that's going on? You know, we are just every day trying to deliver our medicines to patients who have higher medical need. And we're continuing with our R &D pipeline. We're continuing to invest in the U.S. and biotech innovation, and we believe in it. And we also believe the US is the best innovation environment in the world, and we'll continue to do that. I love that optimism. Thank you so much. Great to, and thank you for letting us go kind of wider because you have a great vantage point.
33:28Carol Massar:Catherine, thank you. Good to have you here. Catherine Owen Adams, chief executive officer and board member of Acadia Pharmaceuticals, joining us in our Bloomberg Interactive Broker Studio. Stay with us. More from Bloomberg Businessweek Daily coming up after this.
33:45Support for the show comes from Public. Lately, it feels like there are two types of investing platforms. Some are traditional brokerages that haven't changed much in decades, and others feel less like investing and more like a game. Public is positioned differently. It's an investing platform for people who are serious about building their wealth. On Public, you can build a portfolio of stocks, options, bonds, crypto without all the bugs or the confetti. Retirement accounts, Yep. High yield cash. Yes, again. They even have direct indexing. Public has modern design, powerful tools, and customer support that actually helps.
34:20Go to public.com slash market and earn an uncapped 1 % bonus when you transfer your portfolio. That's public.com slash market.
34:40See complete disclosures at public.com slash disclosures.
34:44Carol Massar:Small businesses are the pulse of every community. They bring people together, create opportunities, and drive growth. With a widespread presence in communities across the country, Chase for Business supports small business owners at a local level. That makes it possible for you to connect, learn from each other, and grow together. There's a real commitment to seeing small businesses succeed. The Chase for Business team has knowledge and expertise that span a wide range of financial areas. They can help you make more informed decisions as you navigate the complexities of running your business.
35:15Carol Massar:They'll help your business grow with individual guidance and convenient digital tools all in one place. With that guidance and your determination, you can take your business farther and help build a brighter future for your community. Learn more at chase.com slash business. Chase for business. Make more of what's yours. The Chase mobile app is available for select mobile devices. Message and data rates may apply. JPMorgan Chase Bank N.A., member FDIC. Copyright 2026, JPMorgan Chase & Company. Deadlines move, plans change, and sometimes opportunities pop up out of nowhere. When you need branded gear fast, 4imprint is ready to deliver.
35:544imprint offers hundreds of promotional products in their 24-hour category. Everything from custom apparel, bags, and drinkware to writing tools, trade show staples, and high-tech gear. At 4imprint, they're focused on getting the details right, printing your logo with precision, packing your order with care, and shipping it out fast. And it's backed by their 360-degree guarantee. That's 4imprint's promise your order will show up right on time, just the way you planned it. That's what it means to be 4imprint certain. So, if you're prepping for a last-minute event or jumping on a big opportunity, you don't have to settle or scramble.
36:29With 4imprint, fast, reliable service and peace of mind are built right in. Check out their full 24-hour selection at 4imprint.com. 4imprint, for certain.
36:42Carol Massar:You're listening to the Bloomberg Business Week Daily Podcast. Catch us live weekday afternoons from 2 to 5 Eastern. Listen on Apple CarPlay and Android Auto with the Bloomberg Business App, or watch us live on YouTube. I want to bring in Aaron Mulvijo, JP Morgan Asset Management the executive director in global alternative strategist. He joins us here in the Bloomberg Interactive Brokers Studio. We want to talk alternatives. We want to talk about the Fed meeting this week. We want to talk about the macro environment and private credit. But I think the thing that we want to start with is the conflict in Iran and sort of how, as it enters its third week, how it's changed your view or not changed your view of the macroeconomic environment.
37:23Yeah, that's obviously what everybody's focused on right now. I think coming into the Fed meeting, we don't expect a change in interest rates, but what we'll be looking at will be the commentary out of the FOMC and what we're seeing in the dot plot and how much inflation is reflected in that. Because inflation is coming out of the higher oil prices, right? We're not on$100 a barrel anymore, but we're at much higher prices. So in other words, you want to know, is this transitory or not? Exactly. How long, the key question is how long is the war going to continue? When will it end? And what will the situation be like when it ends?
37:56Fortunately, You know the answer to all that, Carol.
37:59Carol Massar:I absolutely do. That's why I'm still here. Okay. No, Aaron, I want to ask you, you guys, JPMorgan Asset Management, $4.1 trillion in assets under supervision. We're talking alternatives, fixed income, equities,
38:13Carol Massar:lots of different areas of the marketplace. Give us an idea, first of all, certainly from either institutional investors or some of your investors, what are you hearing since this war began, since this year began, which is safe to say with Venezuela, and the US invasion there, things haven't necessarily started as we anticipated. No, they certainly haven't. I think in public markets, performance has been fairly lackluster. Yeah. As I looked just before coming in here, we're about 2.5 % down in the S &P. A balanced 60-40 portfolio of 60 % stock, 40 % bonds is negative so far year to date. And so that's got investors looking at where can they get alternative sources of yield, alternative returns, which private markets can be a provider of.
38:59Carol Massar:Even with all the worries that are out there? Yeah, absolutely. Give us an idea. You look across the space. Yeah. So I'll take one, right, which is an interesting one that's kind of been at a geopolitical hedge, is transportation, so shipping, private shipping companies that are shipping funds, right? And counterintuitive because we expect when there's a geopolitical issue, shipping can slow down. But what's actually happening with the Strait of Hormuz closed effectively is all that oil and gas has got to come from somewhere else. And it's been brought by ships that are traveling longer distances to get there.
39:32So think about LNG, for example. 25 % of the liquid natural gas comes from Qatar. That can't get out of the Strait. And so more of it's coming from the United States and elsewhere. That's traveling on ships. So those ships have to go further to get to their destinations. And that's a benefit for transportation companies and funds.
39:48Carol Massar:Okay, but are you saying then investors should make that shift or shift to that exposure because you think this is going to be a longer conflict? Because if you don't, then why would you make that shift? The challenging thing, right, with alternatives and private markets is it takes time to get exposure. Yeah. Right, so I think what we really need to be thinking about is… But would you have wanted the exposure before this, then… It certainly would be nice to have the exposure before coming into this, right? But what's the next best thing is to think about what's the economic situation going to be like coming out of this.
40:18We probably need to think about inflation a little bit more and about counteracting that inflation that could persist even after the conflict resolves. Because it's not that easy. You've got a lot of oil can feed into the economy a lot of ways. You don't think the straight is going to go back.
40:32Carol Massar:The straight of hormones is just going to go back to the way it was. It's a lot harder to start oil production than it is to shut it down. So it's going to take some time for those refineries to get back going. And so we might see inflation drag on further. And that means looking at assets that have that inflation hedging characteristic, like infrastructure is one. You were just talking about data centers and AI. Well, what's powering those data centers often is private infrastructure companies, energy companies. And so that can be an inflation hedge in itself. Let's say there is some sort of ceasefire and things do go back to, I'm definitely not going to say normal.
41:09I'm not going to say the way they are because I don't think those two things are possible. But there are ships crossing the Strait of Hormuz again. How long does it take for those higher oil prices to sort of come out of our economy? So what we can look at is the futures markets. So we're looking at futures for April right now, trading around$90 a barrel, right? That's expectations of markets. If we look at December, we're back down to$70,$75 a barrel, right? So somewhere between that, it's going to take a matter of weeks to actually bring those prices back down.
41:43Carol Massar:Or months, as you see. Or potentially months. And really every day that the conflict continues could be multiple days of bringing that back to normal. Because a lot of people's expectations now are baking in higher prices going forward. Our investors just got about 20, 25 seconds. Aaron, are investors looking to put more money to work or are they just kind of sitting tight right now? I think they're reassessing their portfolio for the future in terms of potentially higher inflation expectations and wanting to be protected from that. All right, going to leave it there. Aaron, thank you. Really appreciate it.
42:16Carol Massar:Aaron Mulvigal, he is J.P. Morgan Asset Management Executive Director and Global Alternative Strategist joining us right here in our Bloomberg Interactive Brokers Studio. This is the Bloomberg Business Week Daily podcast, available on Apple, Spotify, and anywhere else you get your podcasts. Listen live weekday afternoons from 2 to 5 p.m. Eastern on Bloomberg.com, the iHeartRadio app, TuneIn, and the Bloomberg Business app. You can also watch us live every weekday on YouTube and always on the Bloomberg Terminal.
42:55Carol Massar:If you follow markets, you know the value of long-term thinking. You plan, you diversify, you prepare for volatility. But even the best strategies can't prevent every bad day. For more than 75 years, Cincinnati Insurance has helped individuals and businesses navigate tough moments with expertise, personal attention, and independent agents who focus on relationships, not transactions. the Cincinnati insurance companies. Let them make your bad day better. Find an agent at CINFIN.com. From coast to coast, unlock adventure at Red Lion Hotels by Sinesta, where restful sleep, friendly service, and trusted local knowledge are part of every stay.
43:40Red Lion makes it easy to feel welcomed, comfortable, and connected wherever the road takes you. Whether you're traveling for business or pleasure, you can spend less and make more of every trip. When you sign up for Sinesta Travel Pass, you'll get their best rates instantly. Go to Sinesta.com to book your stay and unlock the best rates with Sinesta Travel Pass. Here today, roam tomorrow. Join now at Sinesta.com. Terms and conditions apply.
44:09With Bali from iShares, you get access to both monthly income and growth potential in one simple ETF. It's the best of both worlds. discover bali i shares large cap premium income active etf high shares the market is yours visit www.ishares.com to view perspectives for investment objectives risks fees expenses and other information that you should read and consider carefully before investing risks include principal loss in the use of derivatives which could increase risks and volatility monthly income is not guaranteed prepared by blackrock investments llc
From the publisher
The people, companies and trends shaping the global economy.
Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.
Nvidia, the company at the center of an explosive build-out of AI computing, expects to generate at least $1 trillion from its Blackwell and Rubin chips through the end of 2027.The company had previously forecast that the chips would bring $500 billion in sales by the end of 2026. The latest forecast, delivered by Chief Executive Officer Jensen Huang during the company’s GTC event, extends the outlook.
The forecast underscores the scale of Nvidia’s business, which has been supercharged by demand for chips that develop and run AI models. But the cumulative figure doesn’t suggest a tremendous acceleration in sales growth.
After initially rising as much as 4.8%, the shares soon pared their gains on Monday.A flood of spending on AI chips has turned Nvidia into the world’s most valuable company. But investors have sought more evidence that the market’s growth remains on track. Nvidia is also facing mounting competition from rivals like Advanced Micro Devices Inc., as well as its own customers attempting to produce in-house chips to handle AI.
The company has accelerated its technology development in recent years. Nvidia tries to replace its entire product lineup on an annual basis while adding new components. The next design of its flagship AI processors, appearing in systems in the second half of 2026, is called Vera Rubin. The lineup is named for the pioneering astronomer whose observations provided evidence supporting the existence of dark matter.
Today's show features:
- Ed Ludlow, Bloomberg Tech Co-Host
- Marc Champion, Bloomberg Opinion International Affairs Columnist
- Catherine Owen Adams, Acadia CEO
- Drive to the Close with Aaron Mulvihill, JPMorgan Asset Management Executive Director & Global Alternatives Strategist
See omnystudio.com/listener for privacy information.
